ArticleScientific reports2026
Impact of hospital safety-net status on in-hospital and short-outcomes after hematopoietic stem cell transplantation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Safety-net hospitals (SNHs) cater to the medical needs of underserved populations, but their impact on the outcomes of hematopoietic stem cell transplantation (HSCT) remains unclear. The aim of this study was to evaluate the relationship between safety-net status and posttransplant outcomes using the National Readmission Database (NRD), including in-hospital mortality, in-hospital complications, and readmission. This was a retrospective cohort study. Adult patients who underwent allogeneic or autologous HSCT were identified using ICD-9 and ICD-10 procedure codes. Hospitals were classified as SNHs or non-SNHs based on the proportion of Medicaid patients they served. A total of 30,924 patients were treated in the SNHs group and 99,582 in the non-SNHs group. The incidence of in-hospital complications was higher in SNHs. Among those who underwent autologous HSCT (auto-HSCT), in-hospital mortality (2.7% vs. 2.3%; OR = 1.14, 95% CI: 1.02-1.27; P = 0.024) and 30-day readmission rates (16.3% vs. 15.2%; aOR = 1.05, 95% CI: 1.02-1.09; P < 0.001) were modestly higher in SNHs. Similarly, among patients undergoing allogeneic HSCT (allo-HSCT), those treated at SNHs had slightly higher in-hospital mortality (6.5% vs. 5.1%; OR = 1.24, 95% CI: 1.07-1.44; P < 0.001) and 30-day readmission rates (31.6% vs. 28.0%; aOR = 1.13, 95% CI: 1.05-1.23; P = 0.002). However, the magnitude of these differences was modest. These findings should be interpreted with caution given the observational design. While the results may suggest potential disparities in care, further studies are needed to clarify whether the observed differences are driven by patient-level or hospital-level factors and to determine whether targeted interventions may be beneficial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.